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Abstract
Purpose—The Patient-Reported Outcomes Measurement Information System (PROMIS®) 
initiative was developed to advance the methodology of PROs applicable to chronic diseases. 
Chronic obstructive pulmonary disease (COPD) is a progressive chronic disease associated with 
poor health. This study was designed to examine the correlation of PROMIS health-related quality 
of life (HRQOL) scales and clinical measures among COPD patients.
Methods—A cross-sectional analysis was conducted comparing patients who were stable (n = 
100) with those currently experiencing a COPD exacerbation (n=85). All PROMIS measures for 
adults available at the time of the study (2008), disease-targeted and other HRQOL instruments, 
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health literacy, percent predicted FEV1, and a 6-minute walk distance were assessed when patients 
were considered clinically stable.
Results—Stable COPD patients reported significantly (p≤0.05) better health-related quality of 
life on PROMIS domains than patients experiencing an exacerbation. PROMIS domain scores 
were significantly (p≤0.01) correlated with each of legacy measures. Six-minute walk scores were 
most highly correlated with the PROMIS physical function domain scores (r=0.53) followed by 
the fatigue (r=-0.26), social (r=0.24) and to a lesser extent depression (r=-0.23) and anxiety 
(r=-0.22) domain scores. Percent predicted FEV1 score was significantly associated with PROMIS 
physical function scores (r=0.27).
Conclusion—This study provides support for the validity of the PROMIS measures in COPD 
patients.
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patient-reported outcomes; health-related quality of life; chronic obstructive pulmonary disease
Introduction
Clinical measures are critically important but may not reflect the day-to-day functioning and 
well-being of patients with chronic diseases. The Patient Reported Outcomes Measurement 
Information System (PROMIS®) initiative of the National Institutes of Health (NIH) was 
developed to advance methodology and the application of patient-reported outcomes (PROs) 
among patients with chronic diseases for use in research and clinical practice [1].
Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease characterized by 
airflow limitation that is not fully reversible [4]. It is a prevalent condition that ranks in the 
top 5 for leading causes of death worldwide and in the top 3 in the U.S. [2,3]. COPD is 
characterized by episodes of exacerbation that require acute therapies and sometimes 
hospitalization that are associated with declines in health-related quality of life (HRQOL) 
[5].
COPD represents a potentially informative target condition for evaluating the validity of the 
PROMIS instruments for several reasons. Stable COPD is associated with relatively poor 
health status across many areas covered by PROMIS instruments, including depression, 
anxiety, fatigue, mobility, activities of daily living (ADLs), and social activities, with 
significant declines seen in several of these domains during acute exacerbations of the 
condition [9-13]. One study examined the most important HRQOL domains from the COPD 
patient perspective and these patients identified several relevant PROMIS domains including 
fatigue, physical functioning, social roles and social activities to be most relevant for their 
condition [36]. Another study demonstrated that stable COPD patients with more severe 
lung function had significantly worse PROMIS physical function and social role domain 
scores [37]. Across studies, several different HRQOL instruments including generic and 
COPD-targeted measures have been used to evaluate the impact of COPD on HRQOL. Most 
COPD specific measures correlate weakly with clinical measures such as FEV1 [32-35, 37]. 
Therefore, the best instrument and the relative sensitivity of generic versus condition-
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targeted measures is not generally agreed upon in the literature [5-8]. Since PROMIS 
instruments are designed to be applicable to a range of chronic illnesses, they allow for 
comparisons across a variety of chronic health conditions and studies. Hence, the relative 
validity of PROMIS instruments compared to existing COPD specific instruments is 
important to document.
This aim of this study was to examine the validity of PROMIS scales in a cross-sectional 
comparison of stable patients with COPD and patients with a recent exacerbation. 
Specifically, the validity is evaluated by: 1) exploring the correlations of the PROMIS scales 
with clinical indices such as Forced Expiratory Volume in 1 Second (FEV1) and 6-minute 
walk assessments; 2) evaluating the correlations of PROMIS scales with established COPD-
targeted instruments and 3) comparing PROMIS scale scores between stable COPD patients 
and patients experiencing an exacerbation.
Materials and Methods
Participants
Patients were eligible for inclusion in the study if they met the following criteria:
1. had an established clinical history of COPD in accordance with the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) definition. [14,15]
2. had at least a 10 pack/year history of smoking
3. were 40 years or older
4. read and spoke English
5. had access to and be able to communicate using a touch tone telephone
6. were able to see and interact with a computer screen, mouse, and keyboard.
Two groups of patients with a clinical diagnosis of COPD were eligible for enrollment: 1) 
patients with a stable COPD diagnosis, and 2) patients currently experiencing a COPD 
exacerbation. For those enrolled in the stable group (n=100), the patient needed to be 
exacerbation-free for a minimum of 2 months prior to enrollment. For those enrolled into the 
exacerbation group (n=85), treatment for an exacerbation may have started no more than 3 
days prior to the day of enrollment for patients recruited in the outpatient setting and no 
more than 6 days prior to the day of enrollment for patients recruited in the in-patient 
setting. An exacerbation was defined as a sustained worsening of COPD symptoms from 
stable state from normal day-to-day variations. Criteria for an exacerbation included that it 
was acute in onset, necessitated a change in regular medication [4], and required treatment 
with antibiotics, corticosteroids, hospitalization or a combination of these events [16,17].
Patients were excluded from participation if they had any concurrent medical or psychiatric 
condition that may have precluded participation in this study or completion of self-
administered questionnaires (e.g., moderate to severe dementia and/or severe, uncontrolled 
schizophrenia), had a history of asthma without co-existent COPD as the primary diagnosis, 
or were experiencing a current heart failure exacerbation.
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Participants were recruited from outpatient clinics and hospitals at 4 research sites 
(University of North Carolina Health System, NorthShore University Health System, 
Pittsburgh VA Medical Center, and Durham VA Medical Center). The study was conducted 
in accordance with the amended Declaration of Helsinki and was approved by the 
Institutional Review Board (IRB) at each site. At the time of enrollment, eligible participants 
gave written informed consent and began the baseline assessment.
Study Procedures
For those who were stable at enrollment, the baseline assessment included a questionnaire, 
literacy assessment, percent predicted FEV1, and a 6-minute walk test. For those in 
exacerbation at enrollment, the questionnaire was administered at baseline and the clinical 
measures (FEV1 and a 6-minute walk test) along with the literacy assessment were 
administered when the patient was deemed stable (approximately 3 months after 
exacerbation). This was done because it was difficult for the exacerbators to complete these 
measurements during the time of exacerbation. In addition, all of the analysis involving the 
clinical measures (FEV1 And 6-minute walk test) utilized data obtained when the patients 
were deemed stable (see Data Analysis section). The questionnaire collected information on 
demographics, comorbid conditions, COPD history (symptoms, duration of diagnosis as 
well as the number of exacerbations, hospitalizations, and emergency room (ER) visits 
during past year) and health-related quality of life (HRQOL). Participants self-reported their 
responses on laptop computers in the clinic or in the hospital. Research assistants reviewed 
the clinical chart to abstract variables including clinical characteristics, body mass index 
(BMI) and COPD medications.
Study Measures
One goal of the study was to evaluate the associations between the clinical assessments 
(percent-predicted FEV1 and 6-minute walk) and the HRQOL measures. The measures are 
summarized in Table 1. Included were the PROMIS adult health domains 
(www.nihpromis.org) and several targeted “legacy” measures: St. Georges Respiratory 
Questionnaire (SGRQ), Modified Medical Research Council (MMRC) Dyspnea Scale, 
Functional Assessment of Chronic Illness Therapy (FACIT) Dyspnea Scale, EXAcerbations 
of Chronic pulmonary disease Tool – Patient Reported Outcome (EXACT-PRO)), and the 
Pittsburgh Sleep Quality Index (PSQI) [18-24, 38]. These measures were chosen because 
they are some of the most commonly used HRQOL measures in COPD clinical trials and 
observational studies. The MMRC and FACIT Dyspnea scales assess the impact of dyspnea 
on activities of daily living and physical functioning. The SGRQ is a HRQOL questionnaire 
designed for patients with chronic airflow limitation and evaluates three domains: 1) 
symptoms 2) activities that exacerbate symptoms and 3) areas of disease impact such as 
employment, panic, stigmatization, need for medications, side effects of medications, 
expectations and being in control of health as well as disturbances of daily life. The 
EXACT-PRO measures COPD symptoms and manifestations of exacerbations. Pittsburgh 
Sleep Quality Index evaluates sleep quality and disturbances. Version 1.0 of the PROMIS 
items were used and these PROMIS items can be found by accessing www.nihpromis.org. 
The analysis for this manuscript is cross-sectional and included the initial assessment day for 
the EXACT-PRO. Due to the quantity of data, the longitudinal data collected from the 
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EXACT-PRO diaries and the other PRO measures will be the subject of another manuscript. 
Literacy was assessed using the Short Test of Functional Health Literacy in Adults (S-
TOFHLA) [27].
We anticipated that all of the legacy instruments would be significantly correlated with the 
PROMIS domain scales. Specifically, the PROMIS physical function and social health 
(discretionary social activities and social roles) would be the most strongly correlated for the 
SGRQ, FACIT and MMRC instruments as these had been indicated in another study [37]. 
Because these PROMIS domains (physical functioning and social health) are scored so that 
a higher score represents better health, we hypothesized negative correlations with the 
legacy measures.
A 6-minute walk assessment and percent predicted FEV1 measurements were performed at 
the baseline visit unless the patient was experiencing an exacerbation or feeling too ill, in 
which case these measures were performed when the patient was deemed stable. The 6-
minute walk test measured the distance in meters that a participant is able to walk in a 6-
minute time span [25, 26]. Portable spirometry was used to estimate FEV1 using the 
American Thoracic Society criteria [4].
Scoring of HRQOL Measures
PROMIS 1.0 measures administered assess physical function, pain interference, pain 
behavior, fatigue, anxiety, depression, anger, social roles (SR – satisfaction with 
participation in social roles), discretionary social activities (DSA – satisfaction with 
participation in discretionary social activities) and global health (Table 1). PROMIS 
measures can be administered via static short forms (SF) (SF number of items: physical 
function = 10, pain interference = 6, pain behavior = 7, fatigue = 7, anxiety = 7, depression = 
8, anger = 8, social roles = 7, discretionary social activities = 7, and global health = 10) or 
by computer adaptive testing (CAT). For CAT administration, the next item to be 
administered is based on the participant's prior responses and items are administered until 
the reliability of measurement meets a target threshold (e.g., 0.90). The PROMIS CAT 
parameters (www.assessmentcenter.net) were used to administer the CAT. Any remaining 
SF items that had not yet been administered were presented after the CAT was completed. 
Scores from the CAT and SF (all items) were calculated using item response theory (IRT) 
parameters allowing a CAT score and a SF score for each participant on the same underlying 
metric. PROMIS scores are scored on a T-metric with 50 representing the mean and 10 the 
standard deviation in the U. S. general population. For PROMIS domains of anger, anxiety, 
depression, fatigue, pain behavior and pain interference, higher scores indicate worse health 
and for domains of physical function, DSA, SR, and global health (physical and mental), 
higher scores indicate better health.
The SGRQ contains 3 domains (symptoms, activity, and impacts) and a summary score on a 
0-100 scale with 100 representing the worst HRQOL [18, 38]. The MMRC scale is scored 
on a scale of 0 to 4 (0=not troubled with breathlessness except with strenuous exercise; to 
4=too breathless to leave the house or breathless when dressing or undressing) [19]. To 
perform correlation analysis, the MMRC score was linearly transformed to a 0-100 possible 
range (1=0; 2=25; 3=50; 4=75; 5=100) for some analyses. This was done by subtracting 1 
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from the original MMRC score and multiplying it by 25. The FACIT-Dyspnea Scale 
consists of 20 items that assess dyspnea severity (10 items) and related functional limitations 
(10 items). Lower scores reflect less severity or difficulty completing a task [20]. The PSQI 
is scored on a 0-21 scale with higher scores representing worse sleep quality [24]. The 
EXACT-PRO Daily Dairy total score is computed across the 14 items and has a possible 
range of 0 to 100, with higher values indicating a more severe condition [21-23]. The S-
TOFHLA was scored according to published guidelines and literacy was classified as 
adequate for those individuals scoring range of 23 to 36 and inadequate for those scoring 
0-22 [27].
Data Analysis
A cross-sectional analysis was performed using the baseline evaluations unless otherwise 
specified. Preliminary data were analyzed using descriptive and graphical methods wherever 
applicable, to facilitate interpretation of the data. Data was summarized using descriptive 
statistics (e.g., means and standard deviation for continuous and ordinal variables; count and 
frequency for categorical variables) for demographic variables and all HRQOL and clinical 
measures. All item responses were examined using measures of central tendency (mean, 
median), and spread (standard deviation, range), and response category frequencies. 
Correlations between PROMIS and legacy measures as well as between PROMIS and 
clinical measures were estimated. Only the correlations between PROMIS administered by 
CAT and legacy measures are presented as there were no significant differences noted when 
examining the correlations between PROMIS SF and legacy measures. PROMIS IRT-
calibrated person parameters were used for correlations. As noted earlier, 6-minute walk and 
FEV1 percent predicted scores were collected when all patients were deemed stable. The 
relationship between HRQL (PROMIS and legacy) scores and clinical measures (6MWT 
and FEV1) used the HRQOL assessed at the time the patients were deemed stable. In other 
words, these correlations (PROMIS with clinical measures) were performed at baseline for 
stable patients. For patients experiencing an exacerbation, the PROMIS and clinical 
measures were collected when the patient was deemed stable, which may have been up to 3 
months after the baseline visit.
A two-sample t-test was used to compare scores on the PROMIS domains between the two 
COPD groups (stable versus in an exacerbation). Pearson correlation coefficients of the 
PROMIS measures with clinical measures and the HRQOL legacy measures were 
computed.
Results
The stable COPD patients did not differ substantially from the COPD patients enrolled 
during an exacerbation on BMI, smoking history, percent-predicted FEV1, ability to walk 
greater than 300 meters on 6-minute walk assessment, literacy, gender, race, and presence of 
comorbid conditions. However, exacerbators were significantly younger and had been 
diagnosed for shorter periods of time than stable patients. In addition, the exacerbators 
reported significantly more COPD related hospitalizations, emergency room (ER) visits and 
exacerbations during the past 12 months. Not surprisingly, the exacerbators reported 
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significantly more COPD symptoms and exacerbation-related medications (antibiotics as 
well as systemic steroids)(Table 2).
Table 3 shows the mean PROMIS scores by COPD exacerbation status at enrollment. For all 
domains the stable patients reported significantly better PROMIS scores, whether 
administered via CAT or SF. Similarly, the stable patients reported significantly better 
HRQOL on all of the legacy instruments. PROMIS short form scores were significantly 
correlated (P<0.001) with CAT scores for all domains (physical function r=0.89; pain 
interference r=0.95; pain behavior r=0.97; fatigue r=0.88; anxiety r=0.94; depression r=0.85; 
anger r=0.98, social roles r=0.97; discretionary social activities r=0.95).
All of the PROMIS measures (using CAT) were significantly correlated with the legacy 
instruments except for the PROMIS pain domain measures (Pain Behavior and Pain 
Interference) and the MMRC (Table 4). These results did not differ for PROMIS SF (data 
not shown). Six-minute walk scores were most highly correlated with the PROMIS physical 
function scores, followed by the fatigue, social domains (SR and DSA), and to a lesser 
extent anxiety and depression (Table 5). (Similar correlations were found for PROMIS SF 
and CAT.) Percent-predicted FEV1 scores were significantly correlated with PROMIS 
physical function scores (SF and CAT) as well as with FACIT, MMRC and SGRQ 
(Activities and Total) scores (Table 5).
Discussion
Only a couple of studies have evaluated PROMIS instruments among COPD patients. One 
prior cross-sectional study showed PROMIS scores to be worse for those with COPD than 
those without it [28]. This study used self-reported chronic disease status including COPD, 
did not include any assessment of clinical diagnosis and COPD specific results were not 
reported in detail. Another recent study noted that PROMIS physical function and social 
activity scores decreased with level of lung function measured by GOLD grade [37]. The 
present study is unique in comparing PROMIS scores between stable and exacerbating 
COPD patients. Exacerbators reported significantly worse HRQOL on all domains. This 
study is also one of the first studies to examine the correlations between PROMIS scores and 
clinical indices.
The results of this study for the PROMIS measures were similar whether the administration 
was done using a static short-form or CAT. The availability of PROMIS instruments in both 
CAT and short-form offers researchers flexibility in administration formats. CAT 
administration offers the advantage of minimal participant burden without sacrificing 
measurement precision but requires a computer for administration. Short-forms can be 
accomplished via paper and pencil and thus, does not require a computer for administration 
[39]. Both were developed with rigorous qualitative and quantitative methodology and offer 
the advantages of comparability across conditions, reliability, validity and precision.
Several studies have now confirmed that COPD patients experiencing an exacerbation report 
significantly poorer HRQOL than stable COPD patients using either generic or disease-
targeted measures [5-8]. The results for the disease-targeted measures administered in this 
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study were similar to those previously reported [5-8]. The magnitude of score differences 
between stable and exacerbating patients for the disease-specific measures is substantially 
greater than for the PROMIS measures. This is not unexpected since the disease-specific 
measures would be most likely to demonstrate differences between these two populations as 
compared to a generic measure. Exacerbations of COPD have been reported to lead to 
substantial reductions in HRQOL [29, 30]. In addition, some studies have found that patients 
with worse HRQOL scores on disease-targeted measures are more likely to be hospitalized 
and less likely to survive [29, 30].
Patients with COPD often have several other chronic illnesses. Because it is difficult for 
patients to attribute their symptoms to one disease or treatment versus another, generic 
HRQOL measures may be easier to complete [31]. In this study, comparable findings were 
presented for generic and disease-targeted measures. PROMIS scores were significantly 
correlated with the disease specific legacy instruments. Similar to other reported results [37], 
this study found moderate correlations between the PROMIS domain scores and the FACIT-
Dyspnea (correlation coefficients range 0.31 – 0.78) and mMRC dyspnea (correlation 
coefficients range from 0.11 – 0.55). In addition, the largest correlations with the 6-minute 
walk test were similar for the SGRQ Activities (r = -0.41), the FACIT-Dyspnea and 
Functional Limitations (r = -0.50) and the PROMIS Physical Function (r=0.57) domain 
scores.
The correlations between FEV1 and HRQOL tended to be small in magnitude and similar to 
those reported in another study correlating FEV1 with PROMIS measures [37]. There is a 
sizable literature reflecting the relatively weak correlations of disease-targeted and generic 
HRQL instruments with clinical measures, similar to those found in this study. A recent 
meta analysis reported weighted correlations of -0.29 between SGRQ total score and FEV1 
and -0.34 between SGRQ total score and 6-minute walk [32]. Similarly, weak correlations 
have been noted between generic HRQOL instruments scores and FEV1 assessments (range 
for SF-36 physical functioning summary (PCS) r=0.06 to 0.38, and SF-36 mental health 
summary (MCS) 0.09 to 0.25) [33-35].
One limitation of this study was the small sample size at each site that recruited patients; 
hence, clinical site-specific analyses were not feasible. All study sites underwent extensive 
three-day training on a standardized study protocol to ensure consistent implementation for 
patient recruitment, enrollment and study procedures and to minimize variability among 
sites. Another limitation was that differential item functioning for the two study groups 
(stable and exacerbation patients) was not examined. In addition, for some of the analyses a 
subset of the study patients were utilized due to the fact that not patients completed these 
measures when they were in a stable state. Moreover, the analyses reported here do not 
address longitudinal changes in COPD status; hence, it is difficult to determine whether 
some of the differences seen between stable and exacerbating patients are really due to the 
exacerbation or just different underlying disease severity. These issues will be addressed 
more completely in future manuscripts that incorporate longitudinal components of this 
study.
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The study provides support for the validity of the PROMIS measures and found that they 
performed similarly to legacy measures targeting the impact of COPD on HRQOL. Because 
the PROMIS instruments are designed to be applicable to a range of chronic illnesses, they 
offer some advantages over disease-targeted instruments by allowing for comparisons across 
a variety of chronic health conditions and studies.
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EXACT-PRO EXAcerbations of Chronic pulmonary disease Tool – Patient Reported 
Outcomes
FACIT Functional Assessment of Chronic Illness Therapy
FEV1 forced expiratory volume in 1 second
GOLD Global Initiative for Chronic Obstructive Lung Disease
HRQOL health-related quality of life
IRB Institutional Review Board
IRT item response theory
NIH National Institutes of Health
MRC Medical Research Council Dyspnea Scale
PRO patient reported outcomes
PROMIS Patient Reported Outcomes Measurement Information System
PSQI Pittsburgh Sleep Quality Index
SGRQ St. George's Respiratory Questionnaire
SR social roles
s-TOFLHA Short Test of Functional Health Literacy in Adults
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Table 1
Study Measures
Assessment Mode of Administration Patients with Exacerbation Stable Patients
Demographic data forma Self-administered X X
Clinical data formb Chart abstraction X X
Literacy assessmentc,g Interviewer-administered X X
PROMIS 1.0 Itemsd Self-administered
Physical function CAT/SF X X
Pain interference CAT/SF X X
Pain behavior CAT/SF X X
Fatigue CAT/SF X X
Anxiety CAT/SF X X
Depression CAT/SF X X
Anger CAT/SF X X
Social Roles CAT/SF X X
Discretionary Social Activities CAT/SF X X
Global Health items X X
Legacy Instruments e Self-administered
SGRQ X X
PSQI X X
MMRC Dyspnea X X
FACIT-Dyspnea X X
Exact-PRO Daily Diary Self-administeredf Xf Xf
Clinical Assessments In-person assessment
FEV1 measurements X c X
6 minute walk X c X
a
gender, birthdate, race, ethnicity, smoking history, comorbid conditions, current COPD symptoms, COPD history (type of COPD, current 
medications, duration of disease, number of exacerbation and associated hospitalizations and emergency room visits during the past 12 months)
b
body mass index (BMI), COPD history (type of COPD, current medications, lung function values past 2 years)
c
These measures were performed at baseline visit unless patient was experiencing an exacerbation or feeling too ill during their baseline enrollment 
visit, in which case they were performed when the patient was deemed in a stable state. Forced Expiratory Volume in 1 Second (FEV1) was 
measured via portable spirometry.
d
CAT=computer administered items; SF=short forms
e
SGRQ=St. George's Respiratory Questionnaire; Modified Medical Research Council (MMRC) Dyspnea Scale; Functional Assessment of Chronic 
Illness Therapy (FACIT) Dyspnea Scale; PSQI=Pittsburgh Sleep Quality Index; Exact-PRO= EXAcerbations of Chronic pulmonary disease Tool – 
Patient Reported Outcome
f
administered via computer at baseline visit and then during follow-up via Interactive Voice Response via phone daily
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g
Short Test of Functional Health Literacy in Adults (S-TOFHLA)













Irwin et al. Page 15
Table 2
Baseline Demographic and Clinical Characteristics of Enrolled Patients
Characteristic Stable (n=100) Exacerbation (n=85)
mean (sd) range mean (sd) range p-value
BMI 31.10 (8.5) 18-65 32.10 (11.1) 16-79 n.s.
Smoking Pack Year History 46.48 (27.3) 10-156 48.99 (34.5) 10-180 n.s.
% (n) % (n) p-value
Percent Predicted FEV1
>= 80 5(4) 3(2) n.s.
50-79 42(35) 39(27) n.s.
30-49 39(33) 33(23) n.s.
< 30 14(12) 25(17) n.s.
6 Minute Walk
>300 m 55(46) 43(17) n.s.
Literacy
Adequate 93 (91) 88 (59) n.s.
Age Category
40-49 years 2(2) 9(8) <0.01
50-59 years 28(28) 44(37)
60-69 years 37(37) 29(25)
70+ years 33(33) 18(15)
Gender
Female 43(43) 51(43) n.s.
Race
White 75(75) 73(60) n.s.
Comorbidities
Hypertension 60(56) 62(50) n.s.
Angina 13(12) 30(24) <0.01
CAD 21(20) 25(20) n.s.
CHF 18(17) 19(15) n.s.
MI 20(19) 21(17) n.s.
Liver diagnosis 10(9) 8(6) n.s.
Kidney diagnosis 3(3) 3(2) n.s.
Asthma 29(27) 44(35) 0.03
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Characteristic Stable (n=100) Exacerbation (n=85)
mean (sd) range mean (sd) range p-value
Diabetes 34(32) 31(25) n.s.
Depression 37(35) 44(35) n.s.
Anxiety 33(31) 48(38) 0.05
Sleep Disorder 30(28) 44(36) 0.04
Cancer 24(23) 26(21) n.s.
Length of COPD Diagnosis
<1 yr 4(4) 17(14) 0.03
1-3 yrs 23(23) 24(20)
3-5 yrs 15(15) 17(14)
>5 yrs 57(56) 43(36)
Exacerbations last 12 Months
0 68(67) 7(6) <0.01
1 17(17) 28(24)
2 to 5 13(13) 54(46)
≥6 2(2) 11(9)
COPD Hospitalizations last 12 Months
0 87(84) 15(13) <0.01
1 9(9) 46(39)
2 to 5 4(4) 36(30)
≥6 0(0) 2(2)
COPD ER Visits last 12 Months
0 83(81) 41(35) <0.01
1 9(9) 27(23)
2 to 5 7(7) 29(25)
≥6 1(1) 2(2)
Current COPD Symptoms
SOB worsening 19(19) 80(68) <0.01
Cough worsening 15(15) 61(52) <0.01
Increase sputum/mucous 20(20) 61(51) <0.01
Fever 1(1) 29(25) <0.01
Faster Breathing 11(11) 66(56) <.001
Wheezing 20(20) 78(65) <.001
Other 8(8) 31(26) <0.01
COPD Medications
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Characteristic Stable (n=100) Exacerbation (n=85)
mean (sd) range mean (sd) range p-value
Antibiotics 1(1) 24(20) <0.01
Beta agonists 96(94) 96(80) n.s.
Inhaled steroids 60(59) 63(52) n.s.
Systemic steroids 3(3) 48(40) <0.01
Anticholinergenics 74(72) 77(64) n.s.
n.s.=not significant; NA=not applicable
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Table 3
Mean PROMIS SF, CAT and Legacy Instrument Scores by COPD Exacerbation Status at 
Enrollment
Stable (n=100) Exacerbation (n=85)
PROMIS SF+ mean (sd) mean (sd) p-value
Anger 50 (9) 53 (10) <0.01
Anxiety 53 (10) 60 (8) <0.01
Depression 51 (8) 57 (9) <0.01
Fatigue 55 (9) 63 (8) <0.01
Pain Behavior 53 (11) 57 (10) <0.01
Pain Interference 57 (10) 61 (9) <0.01
Physical Function 37 (6) 34 (7) <0.01
Discretionary Social Activities 46 (8) 42 (8) <0.01
Social Roles 44 (9) 38 (9) <0.01
Global Physical 40 (8) 35 (8) <0.01
Global Mental 45 (9) 43 (9) 0.07
PROMIS CAT+ mean (sd) mean (sd) p-value
Anger 50 (10) 53 (10) 0.02
Anxiety 54 (9) 62 (8) <0.01
Depression 51 (9) 57 (9) <0.01
Fatigue 56 (9) 65 (8) <0.01
Pain Behavior 54 (9) 56 (9) 0.05
Pain Interference 57 (10) 61 (10) <0.01
Physical Function 38 (6) 35 (7) <0.01
Discretionary Social Activities 45 (9) 41 (9) <0.01
Social Roles 43 (9) 39 (9) <0.01
Legacy Instruments* + mean (sd) mean (sd) p-value
FACIT - Dyspnea
Dyspnea 51 (9) 58 (11) <0.01
Functional Limitations 50 (8) 55 (10) 0.0019
SGRQ
Symptoms 53 (22) 76 (15) <0.01
Activities 66 (20) 81 (18) <0.01
Impact 38 (19) 58 (17) <0.01
Total 49 (18) 68 (15) <0.01
PSQI
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Stable (n=100) Exacerbation (n=85)
8 (5) 9 (4) 0.02
EXACT PRO - Day 1
30 (13) 45 (10) <0.01
MMRC - dyspnea
38 (26) 58 (30) <0.01
+
CAT=computer administered items; SF=short forms;
*
SGRQ=St. George's Respiratory Questionnaire; Modified Medical Research Council (MMRC) Dyspnea Scale; FunctionalAssessment of Chronic 
Illness Therapy (FACIT) Dyspnea Scale; PSQI=Pittsburgh Sleep Quality Index; Exact-PRO= EXAcerbations of Chronic pulmonary disease Tool– 
Patient Reported Outcome
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